Maxcyte (MXCT) Gains from Investment Securities (2020 - 2021)
Maxcyte's (MXCT) quarterly Gains from Investment Securities came in at $287200.0 in Q3 2021, up 2688.35% quarter-over-quarter from $10300.0 in Q2 2021.
Powered by 
Analysis
Maxcyte (MXCT) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Maxcyte (MXCT) has reported Gains from Investment Securities for 2 consecutive years, with $287200.0 the latest figure, recorded in Q3 2021.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $287200.0 in Q3 2021; TTM through Dec 2021 was $645400.0, a N/A change from a year earlier, with the FY2021 full-year figure at $645400.0, up 76.1% from the prior year.
- Gains from Investment Securities was $287200.0 for Q3 2021 at Maxcyte, up from $10300.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $347900.0 in Q1 2021 and troughed at $10300.0 in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.43 Bn | 221.37 Bn | 8.34 Bn |
| 2 | Danaher | 144.26 Bn | 139.91 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 40.88 Bn | 39.12 Bn | 1.04 Bn |
| 4 | Illumina | 30.92 Bn | 29.75 Bn | 770.00 Mn |
| 5 | Revvity | 13.86 Bn | 12.84 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.27 Bn | 11.00 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.10 Bn | 8.48 Bn | 345.80 Mn |
| 8 | Repligen | 9.28 Bn | 8.27 Bn | 110.04 Mn |
| 9 | 10x Genomics | 8.74 Bn | 8.18 Bn | 112.50 Mn |
| 10 | Maxcyte | 131.50 Mn | 131.50 Mn | 5.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 287,200.00 |
| Jun 30, 2021 | 10,300.00 |
| Mar 31, 2021 | 347,900.00 |
| Dec 31, 2020 | 167,100.00 |